<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03478020</url>
  </required_header>
  <id_info>
    <org_study_id>AQX-1125-104</org_study_id>
    <nct_id>NCT03478020</nct_id>
  </id_info>
  <brief_title>Oral AQX-1125 and Combination Oral Contraceptive Drug-Drug Interaction Study</brief_title>
  <acronym>DDI-COC</acronym>
  <official_title>Open-Label, Fixed-Sequence 3-Period Study to Determine the Effects of Repeated Oral Dosing of AQX-1125 on the Pharamacokinetics, Safety and Tolerability of a Combination Oral Contraceptive in Healthy Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aquinox Pharmaceuticals (Canada) Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aquinox Pharmaceuticals (Canada) Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, fixed sequence, 4 cycle, drug-drug interaction (DDI) study of AQX-1125
      in healthy female subjects on combination oral contraceptives (COC).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 22, 2017</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of COC taken with AQX-1125</measure>
    <time_frame>8 Weeks (from start of treatment period A to completion of treatment period B)</time_frame>
    <description>To assess the effect of multiple doses of 200 mg AQX-1125 once daily (qd) on the pharmacokinetics (PK) of the COC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to attain maximum observed plasma concentration (tmax) of COC taken with AQX-1125</measure>
    <time_frame>8 Weeks (from start of treatment period A to completion of treatment period B)</time_frame>
    <description>To assess the effect of multiple doses of 200 mg AQX-1125 once daily (qd) on the pharmacokinetics (PK) of the COC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve up to 24 hours (AUC0-24) of COC taken with AQX-1125</measure>
    <time_frame>8 Weeks (from start of treatment period A to completion of treatment period B)</time_frame>
    <description>To assess the effect of multiple doses of 200 mg AQX-1125 once daily (qd) on the pharmacokinetics (PK) of the COC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination rate constant (Kel) of COC taken with AQX-1125</measure>
    <time_frame>8 Weeks (from start of treatment period A to completion of treatment period B)</time_frame>
    <description>To assess the effect of multiple doses of 200 mg AQX-1125 once daily (qd) on the pharmacokinetics (PK) of the COC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination half-life (t1/2) of COC taken with AQX-1125</measure>
    <time_frame>8 Weeks (from start of treatment period A to completion of treatment period B)</time_frame>
    <description>To assess the effect of multiple doses of 200 mg AQX-1125 once daily (qd) on the pharmacokinetics (PK) of the COC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of AQX-1125 200 mg qd administered with the COC</measure>
    <time_frame>16 weeks (from start of pre-treatment cycle 1 to completion of treatment period B)</time_frame>
    <description>Safety and tolerability will be assessed by the severity and frequency of adverse events, which will include any abnormal clinically significant vital signs, laboratory tests, electrocardiogram and physical examination findings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of AQX-1125 taken with COC</measure>
    <time_frame>8 Weeks (from start of treatment period A to completion of treatment period B)</time_frame>
    <description>To assess the PK of 200 mg AQX-1125 qd when given together with the COC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to attain maximum observed plasma concentration (tmax) of AQX-1125 taken with COC</measure>
    <time_frame>8 Weeks (from start of treatment period A to completion of treatment period B)</time_frame>
    <description>To assess the PK of 200 mg AQX-1125 qd when given together with the COC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve up to 24 hours (AUC0-24) of AQX-1125 taken with COC</measure>
    <time_frame>8 Weeks (from start of treatment period A to completion of treatment period B)</time_frame>
    <description>To assess the PK of 200 mg AQX-1125 qd when given together with the COC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination rate constant (Kel) of AQX-1125 taken with COC</measure>
    <time_frame>8 Weeks (from start of treatment period A to completion of treatment period B)</time_frame>
    <description>To assess the PK of 200 mg AQX-1125 qd when given together with the COC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t1/2) of AQX-1125 taken with COC</measure>
    <time_frame>8 Weeks (from start of treatment period A to completion of treatment period B)</time_frame>
    <description>To assess the PK of 200 mg AQX-1125 qd when given together with the COC</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Pre-Treatment, Treatment Cycles A &amp; B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-Treatment: Two cycles of a combined oral contraceptive (COC) taken orally once daily for 21 days followed by 7 COC-free days.
Treatment Period A: COC containing taken orally once daily for 21 days followed by 7 COC-free days.
Treatment Period B: COC taken orally once daily for 21 days, with once daily oral 200 mg AQX-1125 (2 x 100 mg tablets) co-administered from Day 13 to 21, followed by 7 COC-free days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AQX-1125</intervention_name>
    <description>Investigational Drug</description>
    <arm_group_label>Pre-Treatment, Treatment Cycles A &amp; B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combined Oral Contraceptive</intervention_name>
    <description>COC containing 100 ug Levonorgestrel (LNG) and 20 ug Ethinyl Estradiol (EE)</description>
    <arm_group_label>Pre-Treatment, Treatment Cycles A &amp; B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18-45 years, inclusive, at time of signing Informed Consent

          -  Adult females of child bearing potential, who are non-pregnant and non-lactating, and
             must agree to use adequate additional contraception from the start of Treatment Period
             A until 90 days after the last dose of AQX-1125

          -  BMI 18.0 - 35.0 kg/m2

          -  Good physical and mental health based on medical history, physical examination,
             clinical laboratory, ECG and vital signs, as judged by the investigator

        Exclusion Criteria:

          -  Previous participation in the current study

          -  Any clinically significant history of breakthrough bleeding

          -  Using tobacco or other nicotine containing products within 12 months prior to the
             first study-specific COC-cycle intake

          -  History of alcohol abuse or drug addiction

          -  Positive drug and alcohol screen at screening and (each) admission to the clinical
             research center

          -  Average intake of more than 24 units of alcohol per week

          -  Positive screen for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV)
             antibodies or anti-human immunodeficiency virus (HIV) 1 and 2 antibodies

          -  Participation in a drug study within 30 days prior to screening. Participation in more
             than 2 other drug studies in the 10 months prior to (the first) drug administration in
             the current study

          -  Donation or loss of more than 100 mL of blood within 60 days prior to the start of
             Treatment Period A, on Day 1. Donation or loss of more than 1.0 liters of blood in the
             10 months prior to the start of Treatment Period A, on Day 1

          -  Significant and/or acute illness within 5 days prior to Day 1 in Treatment Period A,
             that may impact safety assessments, in the opinion of the investigator

          -  Unsuitable veins for blood sampling
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pre-Menopausal Female Subjects</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeroen van de Wetering, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRA Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Health Sciences - Early Development Serices</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2018</study_first_submitted>
  <study_first_submitted_qc>March 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Contraceptives, Oral, Combined</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

